BioNexus files $100 million shelf registration, $20 million ATM program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities
November 10, 2025 8:00 AM ESTKUALA LUMPUR, Malaysia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (BioNexus or the Company), a biotechnology company advancing precision diagnostics and gene-based technologies across Asia and the U.S., today announced that it has filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC) to register up to $100 million of securities that may be offered from time to time.
Under this shelf, the Company has entered into an Equity Distribution Agreement with Maxim Group LLC, pursuant to which it may, subject to the effectiveness of the... More
